Clinical trials show retatrutide, Eli Lilly's new triple-agonist drug, delivered 24.2% weight loss in 48 weeks and the improvement of other conditions in longer studies.
Original Source:
https://www.foxnews.com/health/what-glp-3s-meet-new-generation-weight-loss-drugs-three-key-ingredients
